Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
NAVARRE PAUL
   2. Issuer Name and Ticker or Trading Symbol
Allergan plc [AGN] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP, President Int'l Brands
(Last)
(First)
(Middle)
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,, COOLOCK, CO.		 3. Date of Earliest Transaction (Month/Day/Year)
06/08/2016
(Street)

DUBLIN, L2 00000		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value $0.0001               4,940 (1) D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) $ 108.86               (2) 02/17/2022 Ordinary Shares 7,752   7,752 D  
Stock Option (Right to buy) $ 131.1               (3) 02/21/2023 Ordinary Shares 8,156   8,156 D  
Stock Option (Right to buy) $ 154.87               (4) 02/21/2024 Ordinary Shares 9,499   9,499 D  
Stock Option (Right to buy) $ 289.75               (5) 02/20/2025 Ordinary Shares 7,726   7,726 D  
Stock Option (Right to buy) $ 307.51               (6) 03/17/2025 Ordinary Shares 8,676   8,676 D  
Performance Based Restricted Stock Unit (7)               (7)   (7) Ordinary Shares 9,344   9,344 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
NAVARRE PAUL
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,
COOLOCK, CO.
DUBLIN, L2 00000		       EVP, President Int'l Brands  

Signatures

 /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person   06/08/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
(2) Vests in four equal annual installments commencing on the first anniversary of the grant date (February 17, 2012).
(3) Vests in four equal annual installments commencing on the first anniversary of the grant date (February 21, 2013).
(4) Vests in four equal annual installments commencing on the first anniversary of the grant date (February 21, 2014).
(5) Vests in four equal annual installments commencing on the first anniversary of the grant date (February 20, 2015).
(6) Vests in five equal annual installments commencing on the first anniversary of the grant date (March 17, 2015).
(7) Represents performance-based restricted share units ("PSUs") which will vest as to one-third of the total grant on each of December 31, 2017, 2018 and 2019, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.